Resalis Therapeutics
Resalis Therapeutics is dedicated to developing RNA-based therapies that address the root causes of complex metabolic disorders. With expertise in non-coding RNA and lipid metabolism, the company is advancing RES-010, a promising therapy currently in Phase 1 clinical trials, targeting obesity and fatty liver disease. The company aims to offer safe, effective, and disease-modifying treatments, expanding its pipeline to include therapies for metabolic diseases with significant unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Resalis Therapeutics
Products
RES-010
A locked nucleic acid (LNA) therapy designed to target and inhibit microRNA miR-22 to address metabolic syndromes, obesity, and fatty liver disease.
RES-020
GalNAc conjugated second-generation miR-22 inhibitory drug candidate being developed for obesity.
RES-010
A locked nucleic acid (LNA) therapy designed to target and inhibit microRNA miR-22 to address metabolic syndromes, obesity, and fatty liver disease.
RES-020
GalNAc conjugated second-generation miR-22 inhibitory drug candidate being developed for obesity.
News & Updates
September 12, Copenhagen
October 11-13, Yokohama, Japan
November 4-6, Stockholm
October 6- 9, Montreal
April 28-30, Pisa, Italy
March 20-22, Basel
September 12, Copenhagen
October 11-13, Yokohama, Japan
November 4-6, Stockholm
October 6- 9, Montreal
April 28-30, Pisa, Italy
March 20-22, Basel